

June 17, 2021
Sawai Pharmaceutical Co., Ltd.

Sawai Launches Eight Generic Drugs with 23 Strengths

Osaka, Japan – June 17, 2021 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) today announced the launch of eight generic drugs with 23 strengths. They will be launched sequentially beginning June 18, 2021. Sawai's product line now includes 327 compounds with 808 strengths.

The list of new products:

1. Eszopiclone Tablets

Generic name:	Eszopiclone	Strengths:	1mg, 2mg, 3mg
Brand products:	Lunesta® Tablets 1mg, 2mg, 3mg		

2. Solifenacin Succinate Tablets, OD Tablets

Generic name:	Solifenacin Succinate	Strengths:	Tablets, OD Tablets: 2.5mg, 5mg
Brand products:	Vesicare® Tablets 2.5mg, 5mg, Vesicare® OD Tablets 2.5mg, 5mg		

3. Zilmlo® Combination Tablets, OD Tablets

Generic name:	Azilsartan·Amlodipine	Strengths:	LD, HD
Brand products:	ZACRAS® Combination Tablets LD&HD		

4. Epinastine Hydrochloride Ophthalmic Solution

Generic name:	Epinastine Hydrochloride	Strengths:	0.05%
Brand products:	ALESION® Ophthalmic Solution 0.05%		

5. Duloxetine Caplules

Generic name:	Duloxetine Hydrochloride	Strengths:	20mg, 30mg
Brand products:	Cymbalta® Capsules 20mg, 30mg		

6. Tadalafil Tablets AD

Generic name:	Tadalafil	Strengths:	20mg
Brand products:	Adcirca® Tablets 20mg		

7. Pemetrexed for Intravenous Infusion, Intravenous Infusion

Generic name:	Pemetrexed	Strengths:	For Intravenous Infusion 100mg, 500mg, 800mg, Intravenous Infusion 100mg, 500mg, 800mg
Brand products:	Alimta® Injection 100mg, 500mg		

8. Deferasirox Granules

Generic name:	Deferasirox	Strengths:	90mg, 360mg
Brand products:	JADENU® Granules Sachet 90mg, 360mg		

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

◆ Contact Information ◆

Public Relations Office, Sawai Pharmaceutical Co., Ltd.

E-mail : koho@sawai.co.jp